{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:40:41Z","timestamp":1789965641218,"version":"4.0.1"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T00:00:00Z","timestamp":1562976000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T00:00:00Z","timestamp":1562976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s00467-019-04301-y","type":"journal-article","created":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T22:33:43Z","timestamp":1563057223000},"page":"1601-1619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Dyslipidemia and cardiovascular health in childhood nephrotic syndrome"],"prefix":"10.1007","volume":"35","author":[{"given":"Pankaj","family":"Hari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Khandelwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Smoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,13]]},"reference":[{"key":"4301_CR1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","volume":"392","author":"DG Noone","year":"2018","unstructured":"Noone DG, Iijima K, Parekh R (2018) Idiopathic nephrotic syndrome in children. Lancet 392:61\u201374","journal-title":"Lancet"},{"key":"4301_CR2","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s12098-012-0776-y","volume":"79","author":"A Sinha","year":"2012","unstructured":"Sinha A, Bagga A (2012) Nephrotic syndrome. Indian J Pediatr 79:1045\u20131055","journal-title":"Indian J Pediatr"},{"key":"4301_CR3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.kint.2016.02.026","volume":"90","author":"ND Vaziri","year":"2016","unstructured":"Vaziri ND (2016) Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int 90:41\u201352","journal-title":"Kidney Int"},{"issue":"Suppl 5","key":"4301_CR4","first-page":"S213","volume":"128","author":"Expert Panel on Integrated Guidelines for Cardiovascular Health Risk Reduction in Children and Adolescents; National Heart Lung, and Blood Institute","year":"2011","unstructured":"Expert Panel on Integrated Guidelines for Cardiovascular Health Risk Reduction in Children and Adolescents; National Heart Lung, and Blood Institute (2011) Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 128(Suppl 5):S213\u2013S256","journal-title":"Pediatrics"},{"key":"4301_CR5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0022-2143(97)90038-X","volume":"130","author":"K Liang","year":"1997","unstructured":"Liang K, Vaziri ND (1997) Gene expression of lipoprotein lipase in experimental nephrosis. J Lab Clin Med 130:387\u2013394","journal-title":"J Lab Clin Med"},{"key":"4301_CR6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s10157-011-0549-3","volume":"16","author":"ND Vaziri","year":"2012","unstructured":"Vaziri ND, Yuan J, Ni Z, Nicholas SB, Norris KC (2012) Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression. Clin Exp Nephrol 16:238\u2013243","journal-title":"Clin Exp Nephrol"},{"key":"4301_CR7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrneph.2015.180","volume":"12","author":"ND Vaziri","year":"2016","unstructured":"Vaziri ND (2016) HDL abnormalities in nephrotic syndrome and chronic kidney disease. Nat Rev Nephrol 12:37\u201347","journal-title":"Nat Rev Nephrol"},{"key":"4301_CR8","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1046\/j.1523-1755.2000.00278.x","volume":"58","author":"CJ Deighan","year":"2000","unstructured":"Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ (2000) Patients with nephrotic-range proteinuria have apolipoprotein C and E deficient VLDL1. Kidney Int 58:1238\u20131246","journal-title":"Kidney Int"},{"key":"4301_CR9","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/ki.2012.244","volume":"82","author":"L Wang","year":"2012","unstructured":"Wang L, Shearer GC, Budamagunta MS, Voss JC, Molfino A, Kaysen GA (2012) Proteinuria decreases tissue lipoprotein receptor levels resulting in altered lipoprotein structure and increasing lipid levels. Kidney Int 82:990\u2013999","journal-title":"Kidney Int"},{"key":"4301_CR10","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1046\/j.1523-1755.2003.00941.x","volume":"63","author":"ND Vaziri","year":"2003","unstructured":"Vaziri ND (2003) Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int 63:1964\u20131976","journal-title":"Kidney Int"},{"key":"4301_CR11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm.3396","volume":"20","author":"LC Clement","year":"2014","unstructured":"Clement LC, Mace C, Avila-Casado C, Joles JA, Kersten S, Chugh SS (2014) Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome. Nat Med 20:37\u201346","journal-title":"Nat Med"},{"key":"4301_CR12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1042\/BSR20110102","volume":"32","author":"P Zhu","year":"2012","unstructured":"Zhu P, Goh YY, Chin HF, Kersten S, Tan NS (2012) Angiopoietin-like 4: a decade of research. Biosci Rep 32:211\u2013219","journal-title":"Biosci Rep"},{"key":"4301_CR13","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1194\/jlr.P015867","volume":"52","author":"MR Robciuc","year":"2011","unstructured":"Robciuc MR, Naukkarinen J, Ortega-Alonso A, Tyynismaa H, Raivio T, Rissanen A, Kaprio J, Ehnholm C, Jauhiainen M, Pietilainen KH (2011) Serum angiopoietin-like 4 protein levels and expression in adipose tissue are inversely correlated with obesity in monozygotic twins. J Lipid Res 52:1575\u20131582","journal-title":"J Lipid Res"},{"key":"4301_CR14","doi-asserted-by":"crossref","first-page":"F662","DOI":"10.1152\/ajprenal.00046.2008","volume":"295","author":"Y Zhou","year":"2008","unstructured":"Zhou Y, Zhang X, Chen L, Wu J, Dang H, Wei M, Fan Y, Zhang Y, Zhu Y, Wang N, Breyer MD, Guan Y (2008) Expression profiling of hepatic genes associated with lipid metabolism in nephrotic rats. Am J Physiol Ren Physiol 295:F662\u2013F671","journal-title":"Am J Physiol Ren Physiol"},{"key":"4301_CR15","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1046\/j.1523-1755.2003.00911.x","volume":"63","author":"ND Vaziri","year":"2003","unstructured":"Vaziri ND, Sato T, Liang K (2003) Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis. Kidney Int 63:1756\u20131763","journal-title":"Kidney Int"},{"key":"4301_CR16","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1046\/j.1523-1755.2002.00319.x","volume":"61","author":"ND Vaziri","year":"2002","unstructured":"Vaziri ND, Liang K (2002) Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome. Kidney Int 61:1769\u20131775","journal-title":"Kidney Int"},{"key":"4301_CR17","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/ki.1996.388","volume":"50","author":"ND Vaziri","year":"1996","unstructured":"Vaziri ND, Liang KH (1996) Down-regulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int 50:887\u2013893","journal-title":"Kidney Int"},{"key":"4301_CR18","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/ndt\/gft439","volume":"29","author":"S Liu","year":"2014","unstructured":"Liu S, Vaziri ND (2014) Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome. Nephrol Dial Transplant 29:538\u2013543","journal-title":"Nephrol Dial Transplant"},{"key":"4301_CR19","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.metabol.2007.05.007","volume":"56","author":"CH Kim","year":"2007","unstructured":"Kim CH, Kim HJ, Mitsuhashi M, Vaziri ND (2007) Hepatic tissue sterol regulatory element binding protein 2 and low-density lipoprotein receptor in nephrotic syndrome. Metabolism 56:1377\u20131382","journal-title":"Metabolism"},{"key":"4301_CR20","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1053\/j.ajkd.2013.10.042","volume":"63","author":"K Jin","year":"2014","unstructured":"Jin K, Park BS, Kim YW, Vaziri ND (2014) Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study. Am J Kidney Dis 63:584\u2013589","journal-title":"Am J Kidney Dis"},{"key":"4301_CR21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-119-4-199308150-00002","volume":"119","author":"C Wanner","year":"1993","unstructured":"Wanner C, Rader D, Bartens W, Kramer J, Brewer HB, Schollmeyer P, Wieland H (1993) Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med 119:263\u2013269","journal-title":"Ann Intern Med"},{"key":"4301_CR22","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1523-1755.2004.00737.x","volume":"66","author":"F Kronenberg","year":"2004","unstructured":"Kronenberg F, Lingenhel A, Lhotta K, Rantner B, Kronenberg MF, Konig P, Thiery J, Koch M, von Eckardstein A, Dieplinger H (2004) Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: impact on lipid-lowering therapy? Kidney Int 66:348\u2013354","journal-title":"Kidney Int"},{"key":"4301_CR23","doi-asserted-by":"crossref","first-page":"F823","DOI":"10.1152\/ajprenal.2001.280.5.F823","volume":"280","author":"ND Vaziri","year":"2001","unstructured":"Vaziri ND, Liang K, Parks JS (2001) Acquired lecithin-cholesterol acyltransferase deficiency in nephrotic syndrome. Am J Physiol Ren Physiol 280:F823\u2013F828","journal-title":"Am J Physiol Ren Physiol"},{"key":"4301_CR24","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1021\/bi952242v","volume":"35","author":"Y Zhao","year":"1996","unstructured":"Zhao Y, Marcel YL (1996) Serum albumin is a significant intermediate in cholesterol transfer between cells and lipoproteins. Biochemistry 35:7174\u20137180","journal-title":"Biochemistry"},{"key":"4301_CR25","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0022-2275(20)41339-2","volume":"33","author":"P Moulin","year":"1992","unstructured":"Moulin P, Appel GB, Ginsberg HN, Tall AR (1992) Increased concentration of plasma cholesteryl ester transfer protein in nephrotic syndrome: role in dyslipidemia. J Lipid Res 33:1817\u20131822","journal-title":"J Lipid Res"},{"key":"4301_CR26","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1046\/j.1523-1755.1999.00585.x","volume":"56","author":"K Liang","year":"1999","unstructured":"Liang K, Vaziri ND (1999) Down-regulation of hepatic high-density lipoprotein receptor, SR-B1, in nephrotic syndrome. Kidney Int 56:621\u2013626","journal-title":"Kidney Int"},{"key":"4301_CR27","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0027-9684(15)30368-0","volume":"103","author":"ND Vaziri","year":"2011","unstructured":"Vaziri ND, Navab K, Gollapudi P, Moradi H, Pahl MV, Barton CH, Fogelman AM, Navab M (2011) Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease. J Natl Med Assoc 103:524\u2013533","journal-title":"J Natl Med Assoc"},{"key":"4301_CR28","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10157-013-0847-z","volume":"18","author":"ND Vaziri","year":"2014","unstructured":"Vaziri ND (2014) Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease. Clin Exp Nephrol 18:265\u2013268","journal-title":"Clin Exp Nephrol"},{"key":"4301_CR29","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1161\/01.ATV.20.8.1998","volume":"20","author":"HC McGill Jr","year":"2000","unstructured":"McGill HC Jr, McMahan CA, Zieske AW, Sloop GD, Walcott JV, Troxclair DA, Malcom GT, Tracy RE, Oalmann MC, Strong JP (2000) Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol 20:1998\u20132004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4301_CR30","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJM198601163140302","volume":"314","author":"WP Newman 3rd","year":"1986","unstructured":"Newman WP 3rd, Freedman DS, Voors AW, Gard PD, Srinivasan SR, Cresanta JL, Williamson GD, Webber LS, Berenson GS (1986) Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. N Engl J Med 314:138\u2013144","journal-title":"N Engl J Med"},{"key":"4301_CR31","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1161\/hc4601.099486","volume":"104","author":"PH Davis","year":"2001","unstructured":"Davis PH, Dawson JD, Riley WA, Lauer RM (2001) Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine Study. Circulation 104:2815\u20132819","journal-title":"Circulation"},{"key":"4301_CR32","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2007-1472","volume":"121","author":"MG Frontini","year":"2008","unstructured":"Frontini MG, Srinivasan SR, Xu J, Tang R, Bond MG, Berenson GS (2008) Usefulness of childhood non-high density lipoprotein cholesterol levels versus other lipoprotein measures in predicting adult subclinical atherosclerosis: the Bogalusa Heart Study. Pediatrics 121:924\u2013929","journal-title":"Pediatrics"},{"key":"4301_CR33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-153-3-201008030-00004","volume":"153","author":"MJ Pletcher","year":"2010","unstructured":"Pletcher MJ, Bibbins-Domingo K, Liu K, Sidney S, Lin F, Vittinghoff E, Hulley SB (2010) Nonoptimal lipids commonly present in young adults and coronary calcium later in life: the CARDIA (Coronary Artery Risk Development in Young Adults) study. Ann Intern Med 153:137\u2013146","journal-title":"Ann Intern Med"},{"key":"4301_CR34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s004670050568","volume":"13","author":"U Querfeld","year":"1999","unstructured":"Querfeld U (1999) Should hyperlipidemia in children with the nephrotic syndrome be treated? Pediatr Nephrol 13:77\u201384","journal-title":"Pediatr Nephrol"},{"key":"4301_CR35","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00467-008-1029-1","volume":"24","author":"MH Kniazewska","year":"2009","unstructured":"Kniazewska MH, Obuchowicz AK, Wielkoszynski T, Zmudzinska-Kitczak J, Urban K, Marek M, Witanowska J, Sieron-Stoltny K (2009) Atherosclerosis risk factors in young patients formerly treated for idiopathic nephrotic syndrome. Pediatr Nephrol 24:549\u2013554","journal-title":"Pediatr Nephrol"},{"key":"4301_CR36","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s00467-004-1460-x","volume":"19","author":"BL Lechner","year":"2004","unstructured":"Lechner BL, Bockenhauer D, Iragorri S, Kennedy TL, Siegel NJ (2004) The risk of cardiovascular disease in adults who have had childhood nephrotic syndrome. Pediatr Nephrol 19:744\u2013748","journal-title":"Pediatr Nephrol"},{"key":"4301_CR37","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1440-1754.1997.tb01591.x","volume":"33","author":"H Tsukahara","year":"1997","unstructured":"Tsukahara H, Haruki S, Hiraoka M, Hori C, Sudo M (1997) Persistent hypercholesterolaemia in frequently relapsing steroid-responsive nephrotic syndrome. J Paediatr Child Health 33:253\u2013255","journal-title":"J Paediatr Child Health"},{"key":"4301_CR38","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.1993.292","volume":"44","author":"JD Ordonez","year":"1993","unstructured":"Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH (1993) The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 44:638\u2013642","journal-title":"Kidney Int"},{"key":"4301_CR39","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/clinchem\/41.6.908","volume":"41","author":"J Joven","year":"1995","unstructured":"Joven J, Simo JM, Vilella E, Camps J, Espinel E, Villabona C (1995) Accumulation of atherogenic remnants and lipoprotein(a) in the nephrotic syndrome: relation to remission of proteinuria. Clin Chem 41:908\u2013913","journal-title":"Clin Chem"},{"key":"4301_CR40","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1440-1797.2012.01575.x","volume":"17","author":"Q Zhang","year":"2012","unstructured":"Zhang Q, Zeng C, Fu Y, Cheng Z, Zhang J, Liu Z (2012) Biomarkers of endothelial dysfunction in patients with primary focal segmental glomerulosclerosis. Nephrology (Carlton) 17:338\u2013345","journal-title":"Nephrology (Carlton)"},{"key":"4301_CR41","first-page":"650","volume":"33","author":"N Hooman","year":"2013","unstructured":"Hooman N, Isa-Tafreshi R, Otukesh H, Mostafavi SH, Hallaji F (2013) Carotid artery function in children with idiopathic nephrotic syndrome. Nefrologia 33:650\u2013656","journal-title":"Nefrologia"},{"key":"4301_CR42","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00467-013-2608-3","volume":"29","author":"C Candan","year":"2014","unstructured":"Candan C, Canpolat N, Gokalp S, Yildiz N, Turhan P, Tasdemir M, Sever L, Caliskan S (2014) Subclinical cardiovascular disease and its association with risk factors in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 29:95\u2013102","journal-title":"Pediatr Nephrol"},{"key":"4301_CR43","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1046\/j.1523-1755.2001.00487.x","volume":"59","author":"LF Fried","year":"2001","unstructured":"Fried LF, Orchard TJ, Kasiske BL (2001) Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 59:260\u2013269","journal-title":"Kidney Int"},{"key":"4301_CR44","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/ki.1994.349","volume":"46","author":"WF Keane","year":"1994","unstructured":"Keane WF (1994) Lipids and the kidney. Kidney Int 46:910\u2013920","journal-title":"Kidney Int"},{"key":"4301_CR45","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1053\/j.ajkd.2015.01.008","volume":"65","author":"BA Warady","year":"2015","unstructured":"Warady BA, Abraham AG, Schwartz GJ, Wong CS, Munoz A, Betoko A, Mitsnefes M, Kaskel F, Greenbaum LA, Mak RH, Flynn J, Moxey-Mims MM, Furth S (2015) Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: the Chronic Kidney Disease in Children (CKiD) cohort. Am J Kidney Dis 65:878\u2013888","journal-title":"Am J Kidney Dis"},{"key":"4301_CR46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrneph.2017.155","volume":"14","author":"S Agrawal","year":"2018","unstructured":"Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE (2018) Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol 14:57\u201370","journal-title":"Nat Rev Nephrol"},{"key":"4301_CR47","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1203\/PDR.0b013e3181647af5","volume":"63","author":"NT El-Melegy","year":"2008","unstructured":"El-Melegy NT, Mohamed NA, Sayed MM (2008) Oxidative modification of low-density lipoprotein in relation to dyslipidemia and oxidant status in children with steroid sensitive nephrotic syndrome. Pediatr Res 63:404\u2013409","journal-title":"Pediatr Res"},{"key":"4301_CR48","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/nm0907-1015","volume":"13","author":"SP Jackson","year":"2007","unstructured":"Jackson SP, Calkin AC (2007) The clot thickens\u2014oxidized lipids and thrombosis. Nat Med 13:1015\u20131016","journal-title":"Nat Med"},{"key":"4301_CR49","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.atherosclerosissup.2018.04.001","volume":"31","author":"PM da Silva","year":"2018","unstructured":"da Silva PM, Duarte JS, von Hafe P, Gil V, de Oliveira JN, de Sousa G (2018) Standardization of laboratory and lipid profile evaluation: a call for action with a special focus in 2016 ESC\/EAS dyslipidaemia guidelines\u2014full report. Atheroscler Suppl 31:e1\u2013e12","journal-title":"Atheroscler Suppl"},{"key":"4301_CR50","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499\u2013502","journal-title":"Clin Chem"},{"key":"4301_CR51","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.2013.280532","volume":"310","author":"SS Martin","year":"2013","unstructured":"Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, Jones SR (2013) Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA 310:2061\u20132068","journal-title":"JAMA"},{"key":"4301_CR52","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.semnephrol.2018.02.009","volume":"38","author":"CB Sethna","year":"2018","unstructured":"Sethna CB, Merchant K, Reyes A (2018) Cardiovascular disease risk in children with kidney disease. Semin Nephrol 38:298\u2013313","journal-title":"Semin Nephrol"},{"key":"4301_CR53","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1542\/peds.107.2.256","volume":"107","author":"E Obarzanek","year":"2001","unstructured":"Obarzanek E, Kimm SY, Barton BA, Van Horn LL, Kwiterovich PO Jr, Simons-Morton DG, Hunsberger SA, Lasser NL, Robson AM, Franklin FA Jr, Lauer RM, Stevens VJ, Friedman LA, Dorgan JF, Greenlick MR, DISC Collaborative Research Group (2001) Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary Intervention Study in Children (DISC). Pediatrics 107:256\u2013264","journal-title":"Pediatrics"},{"key":"4301_CR54","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1161\/CIRCULATIONAHA.107.699447","volume":"116","author":"H Niinikoski","year":"2007","unstructured":"Niinikoski H, Lagstrom H, Jokinen E, Siltala M, Ronnemaa T, Viikari J, Raitakari OT, Jula A, Marniemi J, Nanto-Salonen K, Simell O (2007) Impact of repeated dietary counseling between infancy and 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation 116:1032\u20131040","journal-title":"Circulation"},{"key":"4301_CR55","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2165\/11632810-000000000-00000","volume":"72","author":"MJ Braamskamp","year":"2012","unstructured":"Braamskamp MJ, Wijburg FA, Wiegman A (2012) Drug therapy of hypercholesterolaemia in children and adolescents. Drugs 72:759\u2013772","journal-title":"Drugs"},{"key":"4301_CR56","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglu L, WMM V, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT, ESC Scientific Document Group (2016) 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37:2999\u20133058","journal-title":"Eur Heart J"},{"key":"4301_CR57","doi-asserted-by":"crossref","unstructured":"Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, de Ferranti SD, Dionne JM, Falkner B, Flinn SK, Gidding SS, Goodwin C, Leu MG, Powers ME, Rea C, Samuels J, Simasek M, Thaker VV, Urbina EM, Subcommittee On Sceening and Management of High Blood Pressure in Children (2017) Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 140","DOI":"10.1542\/peds.2017-1904"},{"key":"4301_CR58","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/adc.69.2.179","volume":"69","author":"AR Watson","year":"1993","unstructured":"Watson AR, Coleman JE (1993) Dietary management in nephrotic syndrome. Arch Dis Child 69:179\u2013180","journal-title":"Arch Dis Child"},{"key":"4301_CR59","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00007256-200029020-00003","volume":"29","author":"K Tolfrey","year":"2000","unstructured":"Tolfrey K, Jones AM, Campbell IG (2000) The effect of aerobic exercise training on the lipid-lipoprotein profile of children and adolescents. Sports Med 29:99\u2013112","journal-title":"Sports Med"},{"key":"4301_CR60","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.ajkd.2013.06.002","volume":"62","author":"L Beck","year":"2013","unstructured":"Beck L, Bomback AS, Choi MJ, Holzman LB, Langford C, Mariani LH, Somers MJ, Trachtman H, Waldman M (2013) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. Am J Kidney Dis 62:403\u2013441","journal-title":"Am J Kidney Dis"},{"key":"4301_CR61","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10157-014-0958-1","volume":"19","author":"I Rahul","year":"2015","unstructured":"Rahul I, Krishnamurthy S, Satheesh S, Biswal N, Bobby Z, Lakshminarayanan S (2015) Brachial artery flow-mediated dilatation and carotid intima medial thickness in pediatric nephrotic syndrome: a cross-sectional case-control study. Clin Exp Nephrol 19:125\u2013132","journal-title":"Clin Exp Nephrol"},{"key":"4301_CR62","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1001\/jama.2014.8892","volume":"312","author":"DM Kusters","year":"2014","unstructured":"Kusters DM, Avis HJ, de Groot E, Wijburg FA, Kastelein JJ, Wiegman A, Hutten BA (2014) Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. JAMA 312:1055\u20131057","journal-title":"JAMA"},{"key":"4301_CR63","doi-asserted-by":"crossref","unstructured":"Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, Drogari E (2014) Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev:CD006401","DOI":"10.1002\/14651858.CD006401.pub3"},{"key":"4301_CR64","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1046\/j.1523-1755.2002.00483.x","volume":"62","author":"GK Dogra","year":"2002","unstructured":"Dogra GK, Watts GF, Herrmann S, Thomas MA, Irish AB (2002) Statin therapy improves brachial artery endothelial function in nephrotic syndrome. Kidney Int 62:550\u2013557","journal-title":"Kidney Int"},{"key":"4301_CR65","doi-asserted-by":"crossref","first-page":"422","DOI":"10.5551\/jat.42242","volume":"25","author":"M Harada-Shiba","year":"2018","unstructured":"Harada-Shiba M, Kastelein JJP, Hovingh GK, Ray KK, Ohtake A, Arisaka O, Ohta T, Okada T, Suganami H, Wiegman A (2018) Efficacy and safety of pitavastatin in children and adolescents with familial hypercholesterolemia in Japan and Europe. J Atheroscler Thromb 25:422\u2013429","journal-title":"J Atheroscler Thromb"},{"key":"4301_CR66","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1210\/jc.2004-1541","volume":"90","author":"M Hedman","year":"2005","unstructured":"Hedman M, Matikainen T, Fohr A, Lappi M, Piippo S, Nuutinen M, Antikainen M (2005) Efficacy and safety of pravastatin in children and adolescents with heterozygous familial hypercholesterolemia: a prospective clinical follow-up study. J Clin Endocrinol Metab 90:1942\u20131952","journal-title":"J Clin Endocrinol Metab"},{"key":"4301_CR67","first-page":"23","volume":"25","author":"C Stefanutti","year":"1999","unstructured":"Stefanutti C, Lucani G, Vivenzio A, Di Giacomo S (1999) Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood. Drugs Exp Clin Res 25:23\u201328","journal-title":"Drugs Exp Clin Res"},{"key":"4301_CR68","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1007\/s00467-018-4036-x","volume":"33","author":"P Hari","year":"2018","unstructured":"Hari P, Khandelwal P, Satpathy A, Hari S, Thergaonkar R, Lakshmy R, Sinha A, Bagga A (2018) Effect of atorvastatin on dyslipidemia and carotid intima-media thickness in children with refractory nephrotic syndrome: a randomized controlled trial. Pediatr Nephrol 33:2299\u20132309","journal-title":"Pediatr Nephrol"},{"key":"4301_CR69","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF00862065","volume":"10","author":"JE Coleman","year":"1996","unstructured":"Coleman JE, Watson AR (1996) Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood. Pediatr Nephrol 10:171\u2013174","journal-title":"Pediatr Nephrol"},{"key":"4301_CR70","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0022-3476(97)70213-0","volume":"130","author":"SA Sanjad","year":"1997","unstructured":"Sanjad SA, al-Abbad A, al-Shorafa S (1997) Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy. J Pediatr 130:470\u2013474","journal-title":"J Pediatr"},{"key":"4301_CR71","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0272-6386(89)80038-1","volume":"13","author":"TA Golper","year":"1989","unstructured":"Golper TA, Illingworth DR, Morris CD, Bennett WM (1989) Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria. Am J Kidney Dis 13:312\u2013320","journal-title":"Am J Kidney Dis"},{"key":"4301_CR72","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(88)90870-7","volume":"2","author":"AJ Rabelink","year":"1988","unstructured":"Rabelink AJ, Hene RJ, Erkelens DW, Joles JA, Koomans HA (1988) Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. Lancet 2:1335\u20131338","journal-title":"Lancet"},{"key":"4301_CR73","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/ki.1993.358","volume":"44","author":"ME Thomas","year":"1993","unstructured":"Thomas ME, Harris KP, Ramaswamy C, Hattersley JM, Wheeler DC, Varghese Z, Williams JD, Walls J, Moorhead JF (1993) Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int 44:1124\u20131129","journal-title":"Kidney Int"},{"key":"4301_CR74","first-page":"219","volume":"46","author":"BL Rayner","year":"1996","unstructured":"Rayner BL, Byrne MJ, van Zyl SR (1996) A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Clin Nephrol 46:219\u2013224","journal-title":"Clin Nephrol"},{"key":"4301_CR75","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s10157-015-1216-x","volume":"20","author":"S Nishi","year":"2016","unstructured":"Nishi S, Ubara Y, Utsunomiya Y, Okada K, Obata Y, Kai H, Kiyomoto H, Goto S, Konta T, Sasatomi Y, Sato Y, Nishino T, Tsuruya K, Furuichi K, Hoshino J, Watanabe Y, Kimura K, Matsuo S (2016) Evidence-based clinical practice guidelines for nephrotic syndrome 2014. Clin Exp Nephrol 20:342\u2013370","journal-title":"Clin Exp Nephrol"},{"key":"4301_CR76","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1542\/peds.2008-1559","volume":"124","author":"DS Gipson","year":"2009","unstructured":"Gipson DS, Massengill SF, Yao L, Nagaraj S, Smoyer WE, Mahan JD, Wigfall D, Miles P, Powell L, Lin JJ, Trachtman H, Greenbaum LA (2009) Management of childhood onset nephrotic syndrome. Pediatrics 124:747\u2013757","journal-title":"Pediatrics"},{"key":"4301_CR77","doi-asserted-by":"crossref","unstructured":"Kong X, Yuan H, Fan J, Li Z, Wu T, Jiang L (2013) Lipid-lowering agents for nephrotic syndrome. Cochrane Database Syst Rev: CD005425","DOI":"10.1002\/14651858.CD005425.pub2"},{"key":"4301_CR78","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1046\/j.1523-1755.1999.07128.x","volume":"71","author":"CJ Olbricht","year":"1999","unstructured":"Olbricht CJ, Wanner C, Thiery J, Basten A (1999) Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group. Kidney Int Suppl 71:S113\u2013S116","journal-title":"Kidney Int Suppl"},{"key":"4301_CR79","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000013549","volume":"20","author":"RD Toto","year":"2000","unstructured":"Toto RD, Grundy SM, Vega GL (2000) Pravastatin treatment of very low density, intermediate density and low density lipoproteins in hypercholesterolemia and combined hyperlipidemia secondary to the nephrotic syndrome. Am J Nephrol 20:12\u201317","journal-title":"Am J Nephrol"},{"key":"4301_CR80","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1159\/000065021","volume":"91","author":"OA Gheith","year":"2002","unstructured":"Gheith OA, Sobh MA, Mohamed Kel S, El-Baz MA, El-Husseini F, Gazarin SS, Ahmed HA, Rasem MW, Amer GM (2002) Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron 91:612\u2013619","journal-title":"Nephron"},{"key":"4301_CR81","first-page":"143","volume":"5","author":"M Sharma","year":"2004","unstructured":"Sharma M, Nand N, Aggarwal HK, Nand D (2004) Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. J Indian Acad Clin Med 5:143\u2013146","journal-title":"J Indian Acad Clin Med"},{"key":"4301_CR82","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/j.ejim.2008.08.012","volume":"20","author":"O Gheith","year":"2009","unstructured":"Gheith O, Sheashaa H, Abdelsalam M, Shoeir Z, Sobh M (2009) Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidemia: a preliminary report. Eur J Intern Med 20:e57\u2013e61","journal-title":"Eur J Intern Med"},{"issue":"Suppl 3","key":"4301_CR83","first-page":"205","volume":"63","author":"J Ksiazek","year":"2006","unstructured":"Ksiazek J, Niemirska A, Lipka M, Grenda R (2006) Evaluation of arterial intima-media thickness (IMT) in children with idiopathic nephrotic syndrome\u2014preliminary report. Przegl Lek 63(Suppl 3):205\u2013207","journal-title":"Przegl Lek"},{"key":"4301_CR84","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1651-2227.2009.01643.x","volume":"99","author":"FE Mackie","year":"2010","unstructured":"Mackie FE, Rosenberg AR, Harmer JA, Kainer G, Celermajer DS (2010) HMG CoA reductase inhibition and endothelial function in children with chronic kidney disease (CKD)\u2014a pilot study. Acta Paediatr 99:457\u2013459","journal-title":"Acta Paediatr"},{"key":"4301_CR85","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40272-014-0116-y","volume":"17","author":"MJ Braamskamp","year":"2015","unstructured":"Braamskamp MJ, Kusters DM, Avis HJ, Smets EM, Wijburg FA, Kastelein JJ, Wiegman A, Hutten BA (2015) Long-term statin treatment in children with familial hypercholesterolemia: more insight into tolerability and adherence. Paediatr Drugs 17:159\u2013166","journal-title":"Paediatr Drugs"},{"key":"4301_CR86","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1203\/00006450-200206000-00009","volume":"51","author":"BW McCrindle","year":"2002","unstructured":"McCrindle BW, Helden E, Cullen-Dean G, Conner WT (2002) A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatr Res 51:715\u2013721","journal-title":"Pediatr Res"},{"key":"4301_CR87","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/adc.74.2.157","volume":"74","author":"S Tonstad","year":"1996","unstructured":"Tonstad S, Sivertsen M, Aksnes L, Ose L (1996) Low dose colestipol in adolescents with familial hypercholesterolaemia. Arch Dis Child 74:157\u2013160","journal-title":"Arch Dis Child"},{"key":"4301_CR88","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0022-3476(96)70188-9","volume":"129","author":"S Tonstad","year":"1996","unstructured":"Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L (1996) Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr 129:42\u201349","journal-title":"J Pediatr"},{"key":"4301_CR89","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0022-3476(97)70353-6","volume":"130","author":"BW McCrindle","year":"1997","unstructured":"McCrindle BW, O\u2019Neill MB, Cullen-Dean G, Helden E (1997) Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: a randomized, crossover trial. J Pediatr 130:266\u2013273","journal-title":"J Pediatr"},{"key":"4301_CR90","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0272-6386(86)80164-0","volume":"8","author":"A Valeri","year":"1986","unstructured":"Valeri A, Gelfand J, Blum C, Appel GB (1986) Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial. Am J Kidney Dis 8:388\u2013396","journal-title":"Am J Kidney Dis"},{"issue":"231\u2013236","key":"4301_CR91","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/j.jpeds.2009.08.037","volume":"156","author":"EA Stein","year":"2010","unstructured":"Stein EA, Marais AD, Szamosi T, Raal FJ, Schurr D, Urbina EM, Hopkins PN, Karki S, Xu J, Misir S, Melino M (2010) Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr 156(231\u2013236):e231\u2013e233","journal-title":"J Pediatr"},{"key":"4301_CR92","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jpeds.2008.12.044","volume":"154","author":"S Clauss","year":"2009","unstructured":"Clauss S, Wai KM, Kavey RE, Kuehl K (2009) Ezetimibe treatment of pediatric patients with hypercholesterolemia. J Pediatr 154:869\u2013872","journal-title":"J Pediatr"},{"key":"4301_CR93","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jacc.2008.09.002","volume":"52","author":"A van der Graaf","year":"2008","unstructured":"van der Graaf A, Cuffie-Jackson C, Vissers MN, Trip MD, Gagne C, Shi G, Veltri E, Avis HJ, Kastelein JJ (2008) Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 52:1421\u20131429","journal-title":"J Am Coll Cardiol"},{"key":"4301_CR94","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/adc.60.1.34","volume":"60","author":"KA Wheeler","year":"1985","unstructured":"Wheeler KA, West RJ, Lloyd JK, Barley J (1985) Double blind trial of bezafibrate in familial hypercholesterolaemia. Arch Dis Child 60:34\u201337","journal-title":"Arch Dis Child"},{"key":"4301_CR95","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10157-009-0207-1","volume":"13","author":"A Matsunaga","year":"2009","unstructured":"Matsunaga A, Furuyama M, Hashimoto T, Toyoda K, Ogino D, Hayasaka K (2009) Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy. Clin Exp Nephrol 13:659\u2013662","journal-title":"Clin Exp Nephrol"},{"key":"4301_CR96","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jacl.2008.02.003","volume":"2","author":"CM Smalley","year":"2008","unstructured":"Smalley CM, Goldberg SJ (2008) A pilot study in the efficacy and safety of gemfibrozil in a pediatric population. J Clin Lipidol 2:106\u2013111","journal-title":"J Clin Lipidol"},{"key":"4301_CR97","first-page":"40","volume":"44","author":"M Buyukcelik","year":"2002","unstructured":"Buyukcelik M, Anarat A, Bayazit AK, Noyan A, Ozel A, Anarat R, Aydingulu H, Dikmen N (2002) The effects of gemfibrozil on hyperlipidemia in children with persistent nephrotic syndrome. Turk J Pediatr 44:40\u201344","journal-title":"Turk J Pediatr"},{"key":"4301_CR98","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1542\/peds.92.1.78","volume":"92","author":"RB Colletti","year":"1993","unstructured":"Colletti RB, Neufeld EJ, Roff NK, McAuliffe TL, Baker AL, Newburger JW (1993) Niacin treatment of hypercholesterolemia in children. Pediatrics 92:78\u201382","journal-title":"Pediatrics"},{"key":"4301_CR99","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/MED.0b013e3282f76728","volume":"15","author":"RB Goldberg","year":"2008","unstructured":"Goldberg RB, Sabharwal AK (2008) Fish oil in the treatment of dyslipidemia. Curr Opin Endocrinol Diabetes Obes 15:167\u2013174","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"4301_CR100","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1177\/0009922814528032","volume":"53","author":"SD de Ferranti","year":"2014","unstructured":"de Ferranti SD, Milliren CE, Denhoff ER, Steltz SK, Selamet Tierney ES, Feldman HA, Osganian SK (2014) Using high-dose omega-3 fatty acid supplements to lower triglyceride levels in 10- to 19-year-olds. Clin Pediatr (Phila) 53:428\u2013438","journal-title":"Clin Pediatr (Phila)"},{"key":"4301_CR101","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.amjcard.2004.12.014","volume":"95","author":"MM Engler","year":"2005","unstructured":"Engler MM, Engler MB, Malloy MJ, Paul SM, Kulkarni KR, Mietus-Snyder ML (2005) Effect of docosahexaenoic acid on lipoprotein subclasses in hyperlipidemic children (the EARLY study). Am J Cardiol 95:869\u2013871","journal-title":"Am J Cardiol"},{"key":"4301_CR102","unstructured":"Chongviriyaphan N, Tapaneya-Olarn C, Suthutvoravut U, Karnchanachumpol S, Chantraruksa V (1999) Effects of tuna fish oil on hyperlipidemia and proteinuria in childhood nephrotic syndrome. J Med Assoc Thai 82(Suppl 1):S122\u2013S128"},{"key":"4301_CR103","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/MOL.0000000000000234","volume":"26","author":"PM Moriarty","year":"2015","unstructured":"Moriarty PM (2015) Lipoprotein apheresis: present and future uses. Curr Opin Lipidol 26:544\u2013552","journal-title":"Curr Opin Lipidol"},{"key":"4301_CR104","doi-asserted-by":"crossref","unstructured":"Wang A, Richhariya A, Gandra SR, Calimlim B, Kim L, Quek RG, Nordyke RJ, Toth PP (2016) Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia. J Am Heart Assoc 5","DOI":"10.1161\/JAHA.116.003294"},{"key":"4301_CR105","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1053\/j.ajkd.2003.08.012","volume":"42","author":"M Hattori","year":"2003","unstructured":"Hattori M, Chikamoto H, Akioka Y, Nakakura H, Ogino D, Matsunaga A, Fukazawa A, Miyakawa S, Khono M, Kawaguchi H, Ito K (2003) A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 42:1121\u20131130","journal-title":"Am J Kidney Dis"},{"key":"4301_CR106","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10157-014-0996-8","volume":"19","author":"E Muso","year":"2015","unstructured":"Muso E, Mune M, Hirano T, Hattori M, Kimura K, Watanabe T, Yokoyama H, Sato H, Uchida S, Wada T, Shoji T, Yuzawa Y, Takemura T, Sugiyama S, Nishizawa Y, Ogahara S, Yorioka N, Sakai S, Ogura Y, Yukawa S, Iino Y, Imai E, Matsuo S, Saito T (2015) Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS study. Clin Exp Nephrol 19:379\u2013386","journal-title":"Clin Exp Nephrol"},{"key":"4301_CR107","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000437338","volume":"5","author":"E Muso","year":"2015","unstructured":"Muso E, Mune M, Hirano T, Hattori M, Kimura K, Watanabe T, Yokoyama H, Sato H, Uchida S, Wada T, Shoji T, Takemura T, Yuzawa Y, Ogahara S, Sugiyama S, Iino Y, Sakai S, Ogura Y, Yukawa S, Nishizawa Y, Yorioka N, Imai E, Matsuo S, Saito T (2015) A prospective observational survey on the long-term effect of LDL apheresis on drug-resistant nephrotic syndrome. Nephron Extra 5:58\u201366","journal-title":"Nephron Extra"},{"key":"4301_CR108","doi-asserted-by":"crossref","first-page":"E41","DOI":"10.1210\/jc.2014-3066","volume":"100","author":"M Hori","year":"2015","unstructured":"Hori M, Ishihara M, Yuasa Y, Makino H, Yanagi K, Tamanaha T, Kishimoto I, Kujiraoka T, Hattori H, Harada-Shiba M (2015) Removal of plasma mature and furin-cleaved proprotein convertase subtilisin\/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9. J Clin Endocrinol Metab 100:E41\u2013E49","journal-title":"J Clin Endocrinol Metab"},{"key":"4301_CR109","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/CIRCULATIONAHA.115.020912","volume":"134","author":"ME Haas","year":"2016","unstructured":"Haas ME, Levenson AE, Sun X, Liao WH, Rutkowski JM, de Ferranti SD, Schumacher VA, Scherer PE, Salant DJ, Biddinger SB (2016) The role of proprotein convertase subtilisin\/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia. Circulation 134:61\u201372","journal-title":"Circulation"},{"key":"4301_CR110","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1345\/aph.1D587","volume":"38","author":"WA Prescott Jr","year":"2004","unstructured":"Prescott WA Jr, Streetman DA, Streetman DS (2004) The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome. Ann Pharmacother 38:2105\u20132114","journal-title":"Ann Pharmacother"},{"key":"4301_CR111","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ, Oddysey Long Term Investigators (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372:1489\u20131499","journal-title":"N Engl J Med"},{"key":"4301_CR112","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372:1500\u20131509","journal-title":"N Engl J Med"},{"key":"4301_CR113","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12882-017-0644-0","volume":"18","author":"Y Awanami","year":"2017","unstructured":"Awanami Y, Fukuda M, Nonaka Y, Takashima T, Matsumoto K, Yamasaki M, Miyazono M, Ikeda Y (2017) Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report. BMC Nephrol 18:221","journal-title":"BMC Nephrol"},{"key":"4301_CR114","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40265-017-0858-2","volume":"78","author":"B Zheng-Lin","year":"2018","unstructured":"Zheng-Lin B, Ortiz A (2018) Lipid management in chronic kidney disease: systematic review of PCSK9 targeting. Drugs 78:215\u2013229","journal-title":"Drugs"},{"key":"4301_CR115","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/17512433.2017.1362333","volume":"10","author":"A Wiegman","year":"2017","unstructured":"Wiegman A, Hutten BA (2017) Novel pharmacological treatments for children and adolescents with heterozygous familial hypercholesterolemia. Expert Rev Clin Pharmacol 10:919\u2013921","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-019-04301-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-019-04301-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-019-04301-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T21:29:18Z","timestamp":1663968558000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-019-04301-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,13]]},"references-count":115,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["4301"],"URL":"https:\/\/doi.org\/10.1007\/s00467-019-04301-y","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,13]]},"assertion":[{"value":"31 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}